416 results on '"Van Laere, Koen"'
Search Results
2. Synaptic density changes following electroconvulsive therapy: A longitudinal pilot study with PET-MR 11C-UCB-J imaging in late-life depression
3. PET Imaging in Rheumatic Diseases
4. Prevalence, characteristics, and outcome of subclinical vasculitis in polymyalgia rheumatica: a retrospective cohort study
5. Association between vascular FDG uptake during follow-up and the development of thoracic aortic aneurysms in giant cell arteritis
6. Preliminary evidence for preserved synaptic density in late-life depression
7. Serum biomarkers for prognosis and monitoring in asymptomatic Alzheimer’s Disease
8. Novel Targets for Molecular Imaging of Inflammatory Processes of Carotid Atherosclerosis: A Systematic Review
9. Targeted STAT1 therapy for LZTR1‐driven peripheral nerve sheath tumor
10. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes
11. Association Between Vascular 18F-Fluorodeoxyglucose Uptake at Diagnosis and Change in Aortic Dimensions in Giant Cell Arteritis
12. Brain PET Quantification in Neuropsychiatric Research
13. MRI/PET Brain Imaging
14. PSMA PET/CT and PET/MRI in primary staging of prostate cancer and its effect on patient management
15. Multiplex core of the human brain using structural, functional and metabolic connectivity derived from hybrid PET-MR imaging
16. Mild Motor Signs in Healthy Aging Are Associated with Lower Synaptic Density in the Brain
17. Evaluating the pharmacodynamic effects of padsevonil in healthy volunteers using simultaneous [11C]-UCB-J PET and MR Arterial Spin Labeling measurements
18. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease
19. Correction: Schroyen et al. Neuroinflammation and Its Association with Cognition, Neuronal Markers and Peripheral Inflammation after Chemotherapy for Breast Cancer. Cancers 2021, 13, 4198
20. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
21. Not all black colons on [18F]FDG PET are due to metformin
22. 69. Lower Grey Matter Volume is not Related to Synaptic Density in Late Life Depression
23. Higher diagnostic yield of 18F-FDG PET in inflammation of unknown origin compared to fever of unknown origin
24. Differences in Cerebral Glucose Metabolism in ALS Patients with and without C9orf72 and SOD1 Mutations
25. SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement
26. Longitudinal Synaptic Density PET with 11C‐UCB‐J 6 Months After Ischemic Stroke
27. In Vivo Detection of Neurofibrillary Tangles by 18F-MK-6240 PET/MR in Patients With Ischemic Stroke
28. Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI
29. Longitudinal changes in 18F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
30. Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET
31. Simultaneous 18F-FDG PET/MR metabolic and structural changes in visual snow syndrome and diagnostic use
32. The novel M4 PAM PET tracer [11C] MK‐6884: a novel biomarker for measuring target engagement of muscarinic M4 positive allosteric modulators (PAMs) as well as cholinergic tone in patients with Alzheimer’s disease
33. Weighted Gene Co‐Expression Network Analysis for peripheral whole‐blood RNA sequencing in asymptomatic Alzheimer’s disease
34. 18 F‐MK6240 tau in ento‐ and perihinal cortex is related to episodic memory in the earliest stages of Alzheimer’s disease
35. Predictive value of a plasma p‐tau181‐specific assay for amyloid accumulation in asymptomatic Alzheimer’s Disease
36. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients
37. Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue
38. Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
39. Diagnostic accuracy and validation of 18F-fluorodeoxyglucose positron emission tomography scores in a large cohort of patients with polymyalgia rheumatica
40. Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin
41. Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnestic MCI patients
42. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease
43. Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern
44. Patient Safety Considerations for Combined PET/MR Imaging
45. Correction to: Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats
46. Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature
47. Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth
48. Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
49. P546. Preclinical Characterization and Phase 1 Evaluation of the Tolerability, Pharmacokinetics, and Enzyme Occupancy of MK-8189, a Novel PDE10A Inhibitor
50. Cannabinoid receptor availability modulates the magnitude of dopamine release in vivo in the human reward system: A preliminary multitracer positron emission tomography study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.